Camizestrant vs Palazestrant

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Camizestrant · Etcamah

Marketed by AstraZeneca

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT04964934 · Phase 3 · active, not recruiting

This was a randomized, triple-blinded, placebo-controlled Phase III trial with an active comparator (continued aromatase inhibitor) in 315 patients, using progression-free survival (a hard clinical endpoint) as the primary measure. The result, reported via an external source since CT.gov has not yet posted results, showed a clear and highly statistically significant benefit for camizestrant (median PFS 16.0 vs 9.2 months, HR 0.44, p<0.00001), meeting the primary endpoint in the favorable direction.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT04644068 (registry estimate)

Reported efficacy

Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) (From randomization until the earlier of the progression event or death (approximately 2 years)): SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 (met)

Result source: NCT04964934

Palazestrant

Developed by Olema Pharmaceuticals, Inc.

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
Weak signal

NCT04505826 · Phase 1/2 · completed

The study was nonrandomized, unblinded, and single-arm, with participants receiving OP-1250 at sequential dose levels and no placebo or active comparator. Its results were descriptive rather than a formal comparative test: dose-limiting toxicities were 0/42 during dose escalation, while confirmed partial responses included 4/62 participants at 120 mg once daily; therefore, the primary outcomes were not formally met or missed against a control.

Next expected readout: December 2027 · NCT05508906 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCamizestrantPalazestrant
PFS, median—Trial running · NCT07717450—Trial running · NCT06016738
OS, median—Trial running · NCT07717450—Trial running · NCT06016738
ORR—Trial running · NCT07717450—Trial running · NCT06016738
Clinical benefit rate—Trial running · NCT07717450—Trial running · NCT06016738

PFS, median

Camizestrant
—Trial running · NCT07717450
Palazestrant
—Trial running · NCT06016738

OS, median

Camizestrant
—Trial running · NCT07717450
Palazestrant
—Trial running · NCT06016738

ORR

Camizestrant
—Trial running · NCT07717450
Palazestrant
—Trial running · NCT06016738

Clinical benefit rate

Camizestrant
—Trial running · NCT07717450
Palazestrant
—Trial running · NCT06016738
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Camizestrant
SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 NCT04964934 · Phase 3 · design grade: strong · publication or press release
Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81) NCT04588298 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Camizestrant: 4 of 4 rows · Palazestrant: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCamizestrantPalazestrant
Dropout rate
3.3%75 mga
NCT04588298 · Phase 2
show 4 more results
3.3%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
—300 mg QDa
NCT04505826 · Phase 1/2
show 14 more results
0%300 mg QD
NCT04505826 · Phase 1/2
—210 mg QD
NCT04505826 · Phase 1/2
0%210 mg QD
NCT04505826 · Phase 1/2
—150 mg QD
NCT04505826 · Phase 1/2
0%150 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
0%120 mg QD
NCT04505826 · Phase 1/2
—90 mg QD
NCT04505826 · Phase 1/2
0%90 mg QD
NCT04505826 · Phase 1/2
—60 mg QD
NCT04505826 · Phase 1/2
0%60 mg QD
NCT04505826 · Phase 1/2
—30 mg QD
NCT04505826 · Phase 1/2
0%30 mg QD
NCT04505826 · Phase 1/2
Discontinued due to AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
—300 mg QDa
NCT04505826 · Phase 1/2
show 14 more results
—300 mg QD
NCT04505826 · Phase 1/2
—210 mg QD
NCT04505826 · Phase 1/2
—210 mg QD
NCT04505826 · Phase 1/2
—150 mg QD
NCT04505826 · Phase 1/2
—150 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
—90 mg QD
NCT04505826 · Phase 1/2
—90 mg QD
NCT04505826 · Phase 1/2
—60 mg QD
NCT04505826 · Phase 1/2
—60 mg QD
NCT04505826 · Phase 1/2
—30 mg QD
NCT04505826 · Phase 1/2
—30 mg QD
NCT04505826 · Phase 1/2
Serious AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
0%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
28.6%300 mg QDa
NCT04505826 · Phase 1/2
show 14 more results
—300 mg QD
NCT04505826 · Phase 1/2
28.6%210 mg QD
NCT04505826 · Phase 1/2
—210 mg QD
NCT04505826 · Phase 1/2
40%150 mg QD
NCT04505826 · Phase 1/2
—150 mg QD
NCT04505826 · Phase 1/2
19.3%120 mg QD
NCT04505826 · Phase 1/2
57.1%120 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
33.3%90 mg QD
NCT04505826 · Phase 1/2
—90 mg QD
NCT04505826 · Phase 1/2
12.1%60 mg QD
NCT04505826 · Phase 1/2
—60 mg QD
NCT04505826 · Phase 1/2
0%30 mg QD
NCT04505826 · Phase 1/2
—30 mg QD
NCT04505826 · Phase 1/2
Most frequent reported AEs
75 mga
nausea 13.3%
fatigue 6.7%
headache 6.7%
NCT04588298 · Phase 2
show 4 more results
75 mg
visual impairment 20%
headache 10%
photopsia 10%
NCT04588298 · Phase 2
300 mg
hypertension 23.1%
visual impairment 23.1%
photopsia 15.4%
NCT04588298 · Phase 2
150 mg
visual impairment 15.2%
diplopia 12.1%
photopsia 12.1%
NCT04588298 · Phase 2
150 mg
visual impairment 24.1%
diplopia 17.2%
hypertension 13.8%
NCT04588298 · Phase 2
300 mg QDa
nausea 85.7%
vomiting 71.4%
fatigue 57.1%
NCT04505826 · Phase 1/2
show 7 more results
210 mg QD
constipation 57.1%
nausea 57.1%
decreased appetite 42.9%
NCT04505826 · Phase 1/2
150 mg QD
nausea 80%
neutrophil count decreased 40%
vomiting 40%
NCT04505826 · Phase 1/2
120 mg QD
nausea 66.3%
fatigue 28.9%
vomiting 28.9%
NCT04505826 · Phase 1/2
120 mg QD
constipation 42.9%
hypokalaemia 42.9%
nausea 42.9%
NCT04505826 · Phase 1/2
90 mg QD
anxiety 33.3%
nausea 33.3%
photopsia 33.3%
NCT04505826 · Phase 1/2
60 mg QD
nausea 42.4%
fatigue 39.4%
headache 21.2%
NCT04505826 · Phase 1/2
30 mg QD
constipation 40%
diarrhoea 40%
fatigue 40%
NCT04505826 · Phase 1/2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Palazestrant

ORR 0% (n=4)300 mg QD
event count · % of participants
No placebo or comparator arm
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
show 7 more results
0% (n=4)*210 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
0% (n=1)*150 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
6.5% (n=62)*120 mg QD
NCT04505826 · Phase 1/2 · converted to % from 4 Participants as posted
0% (n=5)*120 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
0% (n=4)*90 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
7.1% (n=28)*60 mg QD
NCT04505826 · Phase 1/2 · converted to % from 2 Participants as posted
0% (n=5)*30 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camizestrant's landscape · Palazestrant's landscape